|
|
- Ixion's Director of Research Joins American Diabetes Association Research Grant
- Review Panel
-
 ALACHUA, FL.- September 21, 2001 -Ixion Biotechnology, Inc., announced today that Vijay K. Ramiya, PhD, director of research of the biotechnology company's Diabetes Division, has accepted an invitation to serve as a member of the Research Grant Review Panel of the American Diabetes Association. Ramiya will serve a three-year term, ending June 2004.
- The American Diabetes Association is one of the nation's leading nonprofit health organizations providing diabetes research, information and advocacy. The Association's Research Grant Review Panel determines which grant proposals will receive funding from the Association. The American Diabetes Association provides grant support to new and established investigators. This year, it awarded 46 scientists millions of dollars for research beginning January 2001. Ramiya oversees Ixion's program to grow functioning pancreatic islets in vitro from Islet Producing Stem Cells (IPSCs), which Ixion has established in cell cultures. Transplantation of islets is the only known potential cure for type 1 diabetes. Before joining Ixion, Ramiya, who completed postdoctoral research at the University of Cambridge in England, was a visiting assistant professor in the Laboratory of Immunogenetics at the University of Illinois. He has a Ph.D. in immunology and has an extensive background in insulin-dependent diabetes, having overseen diabetes-related research projects at the University of Florida, and basic immunology projects at the University of Illinois. He is a longtime member of the American Diabetes Association.
- "Being selected to serve on a peer review panel that examines the merit of research proposals aimed at the treatment and prevention of this disease is an honor in the scientific community. Ixion supports the goals of the American Diabetes Association, and we are proud and pleased to have one of our scientists participating in such an important role in research to ultimately find treatments for this disease," said Ammon B. Peck, PhD, Ixion's chief scientist.
- Ixion specializes in the treatment of metabolic disorders, including a stem cell treatment for diabetes and a treatment for oxalate-related diseases, such as kidney stones. Ixion, the only company in the world working with the non-pathogenic oxalate degrading bacterium, O. formigenes, holds worldwide exclusive licenses to patents and pending patents for treatments of diabetes and oxalate-related disorders. The biotech company has demonstrated the feasibility of using adult, somatic stem cells to produce new pancreatic stem cell preparations for the treatment of diabetes.
- For more information about Ixion's current activities and recent news releases, visit Ixion's Web site at www.ixion-biotech.com or call 386-418-1428.
- This news release discusses historical information and includes forward-looking statements that involve a number of risks and uncertainties, such as risks associated with pre-clinical and clinical development in the biotechnology industry, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments and costs of developing, producing and selling products.
- Contacts:
-
-
-
-
-
-
-
-
- Louis G. Kessler, Ph.D.
Ixion Biotechnology, Inc.
386-418-1428 (voice)
386-418-1583 (fax)
Info@ixion-biotech.com
Lisette Hilton
561-392-5649 (voice)
561-392-7496 (fax)
Info@ixion-biotech.com
-
-
-
|
|
